Behandlingen bør afbrydes hos patienter, der udvikler epileptiske anfald, eller hvor der ses en øgning i anfaldsfrekvensen. – Leverinsufficiens:
Treatment should be discontinued in any patient who develops seizures, or where there is an increase in seizure frequency. – hepatic impairment: